ACM
ALXN

Atika Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Atika Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,000
Closed -$925K – 80
2014
Q4 		$925K Buy
+5,000
New +$926K 0.68% 50
2014
Q3 		– Sell
-12,000
Closed -$1.88M – 82
2014
Q2 		$1.88M Buy
+12,000
New +$1.89M 1.52% 31

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Atika Capital Management's ALXN Position: Q1 2015 in Review

Atika Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 5,000 shares — an estimated $925K sold.

Atika Capital Management first reported a position in ALXN in Q2 2014 and held it in 2 quarters. The position peaked at $1.88M in Q2 2014. 566 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

  • Atika Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Atika Capital Management sold 5,000 Alexion Pharmaceuticals shares in Q1 2015, an estimated $925K.
  • Atika Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Atika Capital Management's Alexion Pharmaceuticals position peaked at $1.88M in Q2 2014.
  • 566 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Atika Capital Management's 13F filing for Q1 2015, filed 15 May 2015.